BFRI.NASDAQBiofrontera INC
10-Q: Biofrontera Inc. Reports Q1 2024 Results, Faces Going Concern Uncertainty Despite Financing
Sentiment:
Quarterly Report
Biofrontera Inc. reported a net loss of $10.4 million for Q1 2024 and faces going concern uncertainty, despite securing $7.3 million in financing and reducing inventory costs.
Delay expectedThe company has experienced manufacturing delays with its Xepi product, and expects to receive commercial product in the fourth quarter of 2024.The company has historically experienced delays due to supply chain issues, and there is a possibility that there are additional supply chain challenges.
Capital raiseThe company completed a private placement of preferred stock and warrants, resulting in net proceeds of $7.3 million.The company issued warrants to purchase 8,000 shares of Series B-3 Convertible Preferred Stock at an exercise price of $1,000 per share.As of May 15, 2024, all five investors have exercised the B-3 Preferred Convertible Share Warrants and the Company received net proceeds of $7.4 million.
Worse than expectedThe company's revenue decreased by 9.3% compared to the same period last year.The company's net loss increased to $10.4 million compared to $7.5 million in the same period last year.The company's adjusted EBITDA decreased to -$4.6 million compared to -$4.1 million in the same period last year.
Summary
- Biofrontera Inc. reported a net loss of $10.4 million for the first quarter of 2024, compared to a $7.5 million loss in the same period of 2023.
- The company's revenue decreased by 9.3% to $7.9 million, primarily due to lower Ameluz sales.
- Operating expenses decreased slightly to $13.4 million, driven by lower legal costs and sales and marketing expenses.
- The company's cash and cash equivalents increased to $3.8 million as of March 31, 2024, up from $1.3 million at the end of 2023, due to a $7.3 million capital raise.
- Biofrontera has an accumulated deficit of $110.1 million as of March 31, 2024.
- The company has implemented cost-cutting measures and secured a new supply agreement to improve gross margins to approximately 75% for Ameluz.
- Management believes that the company will have sufficient liquidity for at least one year from the date of the report, but this is dependent on executing its sales plan and controlling costs.
Sentiment
Score: 4
Explanation: The document presents a mixed picture. While the company has secured financing and improved its gross margin, it is still facing significant losses, revenue decline, and going concern uncertainty. The positive developments are overshadowed by the financial challenges and risks.
Positives
- The company secured $7.3 million in net proceeds from a private placement of preferred stock and warrants.
- A new supply agreement is expected to increase gross margins on Ameluz to approximately 75%, reducing cash needs for inventory.
- The company has implemented cost-cutting measures, reducing discretionary expenses by approximately $5.5 million compared to 2023.
- Cash and cash equivalents increased to $3.8 million as of March 31, 2024, up from $1.3 million at the end of 2023.
Negatives
- The company reported a net loss of $10.4 million for Q1 2024.
- Revenue decreased by 9.3% to $7.9 million compared to Q1 2023.
- The company has an accumulated deficit of $110.1 million as of March 31, 2024.
- The company terminated a loan agreement with Midcap Business Credit LLC, incurring a $0.3 million loss on debt extinguishment.
- The company's auditor has raised substantial doubt about the company's ability to continue as a going concern.
Risks
- The company's ability to continue as a going concern is dependent on executing its sales plan, controlling operating costs, and securing additional financing.
- The company may not be able to raise additional capital or debt on acceptable terms, or at all.
- The company is subject to supply chain risks, including potential delays in the delivery of Xepi and the RhodoLED XL.
- The company is involved in ongoing litigation that could have a material impact on its financial position.
- The company is dependent on sales of licensed products from other companies as its sole source of revenue.
Future Outlook
Management believes that the company will have sufficient liquidity and probable financing to meet its funding requirements for at least one year from the date of the report, but this is dependent on executing its sales plan, controlling operating costs, and other possible challenges and unforeseen circumstances.
Management Comments
- Management believes that the company will have sufficient liquidity and probable financing to meet its funding requirements for at least one year from the date of the report.
- Management plans to adhere to the 2024 budget, which includes significant sales and marketing, medical affairs, and dermatology community outreach efforts.
- Management expects the new supply agreement to significantly reduce the cost of inventory in the future.
Industry Context
The company operates in the biopharmaceutical industry, focusing on dermatological conditions. The company's primary product, Ameluz, competes with other treatments for actinic keratoses. The company's financial performance is affected by factors such as seasonality, supply chain issues, and competition from other pharmaceutical and medical device companies.
Comparison to Industry Standards
- Biofrontera's revenue decline of 9.3% in Q1 2024 is concerning, as many pharmaceutical companies aim for consistent growth.
- The company's gross margin improvement to 75% on Ameluz is a positive step, but it needs to be sustained and translated into profitability.
- The company's reliance on a single product, Ameluz, for the majority of its revenue is a risk, as is the dependence on third-party suppliers.
- The company's adjusted EBITDA margin of -57.9% indicates significant operational challenges compared to industry benchmarks.
- The company's accumulated deficit of $110.1 million highlights the need for a clear path to profitability, which is a common challenge for early-stage biopharmaceutical companies.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Executive Officer & Chairman | na | Hermann Luebbert | 2024-05-10 | Amended and restated employment agreement |
| Chief Financial Officer | na | E. Fred Leffler, III | 2024-05-10 | Amended and restated employment agreement |
Legal Proceedings
- Biofrontera is involved in a legal claim filed by DUSA Pharmaceuticals, Inc., Sun Pharmaceutical Industries, Inc., and Sun Pharmaceutical Industries LTD, alleging breach of contract, violation of the Lanham Act, and unfair trade practices.
- The company denies the plaintiffs' claims and intends to defend these matters vigorously.
Related Party Transactions
- The company has a license and supply agreement with Biofrontera Pharma for Ameluz and BF-RhodoLED lamps.
- The company has a service agreement with Biofrontera AG for regulatory support and pharmacovigilance.
- The company has a clinical lamp lease agreement with Biofrontera Bioscience.
- The company has a share purchase agreement with Maruho Co., Ltd.
Stakeholder Impact
- Shareholders face the risk of further losses and potential dilution.
- Employees may be affected by cost-cutting measures and potential restructuring.
- Customers may experience supply chain disruptions and delays.
- Suppliers may be affected by the company's financial challenges.
- Creditors face the risk of non-payment if the company's financial situation does not improve.
Next Steps
- The company will focus on executing its sales plan and controlling operating costs.
- The company will continue to monitor the impacts of the supply chain on its business.
- The company will take control of all clinical trials relating to Ameluz in the US on or before June 1, 2024.
- The company will launch the RhodoLED XL in the second quarter of 2024.
Key Dates
| Date | Description |
|---|---|
| 2021-12-15 | Effective date of the original Employment Agreement with Hermann Luebbert. |
| 2022-02-09 | Formation of Bio-FRI GmbH, a German subsidiary. |
| 2022-10-03 | Effective date of the original Employment Agreement with E. Fred Leffler, III. |
| 2023-07-03 | Effective date of the 1-for-20 reverse stock split. |
| 2024-01-04 | Termination of the Loan and Security Agreement with Midcap Business Credit LLC. |
| 2024-02-13 | Effective date of the Second Amended and Restated License and Supply Agreement with the Ameluz Licensor. |
| 2024-02-19 | Date of the Preferred Purchase Agreement with healthcare-focused institutional investors. |
| 2024-02-22 | Closing date of the private placement, resulting in $7.3 million in net proceeds. |
| 2024-03-31 | End of the first quarter of 2024. |
| 2024-04-24 | Date of the Special Meeting of Stockholders, approving an increase in authorized shares. |
| 2024-05-02 | Board certification and public announcement of achievement of milestones related to the Preferred Warrants. |
| 2024-05-06 | Date of the amendment to the Settlement Agreement with Biofrontera AG. |
| 2024-05-10 | Effective date of the amended and restated employment agreements with Fred Leffler and Hermann Luebbert. |
| 2024-05-13 | Preferred Warrants were exercised to purchase 7,998 shares of Series B-3 Convertible Preferred stock. |
| 2024-05-14 | Preferred Warrants were exercised to purchase 7,998 shares of Series B-3 Convertible Preferred stock. |
| 2024-05-15 | Date of the report and the date all five investors have exercised the B-3 Preferred Convertible Share Warrants. |
Keywords
Biofrontera, Ameluz, Xepi, photodynamic therapy, actinic keratoses, dermatology, biopharmaceutical, financial results, going concern, capital raise
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.